Leavitt Chase C.

Oncternal Therapeutics, Inc. · General Counsel/Secretary

Leavitt Chase C. serves as the General Counsel and Secretary at Oncternal Therapeutics, Inc., a company focused on developing innovative therapies for cancer treatment. His recent SEC Form 4 filings from January 5, 2024, to February 15, 2024, reveal two public disclosures related to his activities within the firm. The most significant disclosure involved a grant/exercise action valued at approximately $130.4K, highlighting his role in the healthcare sector and the financial activities connected to Oncternal Therapeutics (ONCT).

History Trades

CompanyValueActionPriceCurrent Price
Historical insider buys and sells before the latest disclosure date will appear here after more snapshots are available.